Gastrointestinal disease and the kidney

Area of Science:

• Nephrology
• Gastroenterology
• Clinical Pharmacology

Background:

• Renal disease, including insufficiency, end-stage renal disease (ESRD), dialysis, and transplantation, frequently co-occurs with significant gastrointestinal (GI) symptoms.
• Conversely, GI diseases can lead to renal complications.
• Patients with ESRD, on dialysis, or post-transplant are at higher risk for GI complications like erosive disease and bleeding.

Purpose of the Study:

• To evaluate the challenges in selecting pharmacotherapy for GI conditions in patients with renal disease.
• To identify the most suitable acid-suppressing therapies for this patient population.

Main Methods:

• Review of existing literature on GI complications in renal disease patients.
• Analysis of pharmacotherapy selection factors, including renal impact, dosing adjustments, and drug-drug interactions.
• Evaluation of the suitability of different acid-suppressing agents.

Main Results:

• Pharmacotherapy selection for GI conditions in renal disease is complex due to potential negative impacts on compromised renal function, necessary dosing alterations, and drug-drug interactions.
• Proton pump inhibitors (PPIs) are identified as the most appropriate acid-suppressing therapy.
• Newer PPIs, such as rabeprazole, may offer the best therapeutic option.

Conclusions:

• Acid-related GI conditions in patients with renal disease require careful pharmacotherapy selection.
• Proton pump inhibitors are generally well-suited for this population.
• Rabeprazole emerges as a potentially optimal choice for managing acid-related GI issues in patients with concurrent renal disease.